Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma

Satoshi Watanabe; Takashi Sone; Tomoharu Matsui; Kenta Yamamura; Mayuko Tani; Akihito Okazaki; Koji Kurokawa; Yuichi Tambo; Hazuki Takato; Noriyuki Ohkura; Yuko Waseda; Nobuyuki Katayama; Kazuo Kasahara

doi:10.1016/j.lungcan.2013.06.003

Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma

Satoshi Watanabe, Takashi Sone, Tomoharu Matsui, Kenta Yamamura, Mayuko Tani, Akihito Okazaki, Koji Kurokawa, Yuichi Tambo, Hazuki Takato, Noriyuki Ohkura, Yuko Waseda, Nobuyuki Katayama, Kazuo Kasahara^*

^*Corresponding author for this work

Medicine, Pulmonary Division

Research output: Contribution to journal › Article › peer-review

76 Scopus citations

Abstract

We report the case of a 52-year-old woman with lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor (TKI) therapy. After disease progression, histological examination of a secondary biopsy specimen revealed small-cell lung cancer (SCLC) that was sensitive to standard SCLC treatment. Tumor markers, including ProGRP and NSE, were elevated. Transformation to SCLC is a mechanism for acquired resistance to EGFR-TKI therapy. Secondary biopsy is important for evaluation of genetic and histological changes and selection of appropriate treatment. Furthermore, ProGRP and NSE may be useful for early detection of SCLC transformation in cases resistant to EGFR-TKI therapy.

Original language	English (US)
Pages (from-to)	370-372
Number of pages	3
Journal	Lung Cancer
Volume	82
Issue number	2
DOIs	https://doi.org/10.1016/j.lungcan.2013.06.003
State	Published - Nov 2013

Keywords

Adenocarcinoma
EGFR tyrosine kinase inhibitors
NSE
ProGRP
Resistance
Small cell lung cancer
Transformation

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2013.06.003

Cite this

Watanabe, S., Sone, T., Matsui, T., Yamamura, K., Tani, M., Okazaki, A., Kurokawa, K., Tambo, Y., Takato, H., Ohkura, N., Waseda, Y., Katayama, N., & Kasahara, K. (2013). Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma. Lung Cancer, 82(2), 370-372. https://doi.org/10.1016/j.lungcan.2013.06.003

@article{2a0d59a711f24d58b4d43ba010352ec7,

title = "Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma",

abstract = "We report the case of a 52-year-old woman with lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor (TKI) therapy. After disease progression, histological examination of a secondary biopsy specimen revealed small-cell lung cancer (SCLC) that was sensitive to standard SCLC treatment. Tumor markers, including ProGRP and NSE, were elevated. Transformation to SCLC is a mechanism for acquired resistance to EGFR-TKI therapy. Secondary biopsy is important for evaluation of genetic and histological changes and selection of appropriate treatment. Furthermore, ProGRP and NSE may be useful for early detection of SCLC transformation in cases resistant to EGFR-TKI therapy.",

keywords = "Adenocarcinoma, EGFR tyrosine kinase inhibitors, NSE, ProGRP, Resistance, Small cell lung cancer, Transformation",

author = "Satoshi Watanabe and Takashi Sone and Tomoharu Matsui and Kenta Yamamura and Mayuko Tani and Akihito Okazaki and Koji Kurokawa and Yuichi Tambo and Hazuki Takato and Noriyuki Ohkura and Yuko Waseda and Nobuyuki Katayama and Kazuo Kasahara",

year = "2013",

month = nov,

doi = "10.1016/j.lungcan.2013.06.003",

language = "English (US)",

volume = "82",

pages = "370--372",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

Watanabe, S, Sone, T, Matsui, T, Yamamura, K, Tani, M, Okazaki, A, Kurokawa, K, Tambo, Y, Takato, H, Ohkura, N, Waseda, Y, Katayama, N & Kasahara, K 2013, 'Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma', Lung Cancer, vol. 82, no. 2, pp. 370-372. https://doi.org/10.1016/j.lungcan.2013.06.003

TY - JOUR

T1 - Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma

AU - Watanabe, Satoshi

AU - Sone, Takashi

AU - Matsui, Tomoharu

AU - Yamamura, Kenta

AU - Tani, Mayuko

AU - Okazaki, Akihito

AU - Kurokawa, Koji

AU - Tambo, Yuichi

AU - Takato, Hazuki

AU - Ohkura, Noriyuki

AU - Waseda, Yuko

AU - Katayama, Nobuyuki

AU - Kasahara, Kazuo

PY - 2013/11

Y1 - 2013/11

N2 - We report the case of a 52-year-old woman with lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor (TKI) therapy. After disease progression, histological examination of a secondary biopsy specimen revealed small-cell lung cancer (SCLC) that was sensitive to standard SCLC treatment. Tumor markers, including ProGRP and NSE, were elevated. Transformation to SCLC is a mechanism for acquired resistance to EGFR-TKI therapy. Secondary biopsy is important for evaluation of genetic and histological changes and selection of appropriate treatment. Furthermore, ProGRP and NSE may be useful for early detection of SCLC transformation in cases resistant to EGFR-TKI therapy.

AB - We report the case of a 52-year-old woman with lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor (TKI) therapy. After disease progression, histological examination of a secondary biopsy specimen revealed small-cell lung cancer (SCLC) that was sensitive to standard SCLC treatment. Tumor markers, including ProGRP and NSE, were elevated. Transformation to SCLC is a mechanism for acquired resistance to EGFR-TKI therapy. Secondary biopsy is important for evaluation of genetic and histological changes and selection of appropriate treatment. Furthermore, ProGRP and NSE may be useful for early detection of SCLC transformation in cases resistant to EGFR-TKI therapy.

KW - Adenocarcinoma

KW - EGFR tyrosine kinase inhibitors

KW - NSE

KW - ProGRP

KW - Resistance

KW - Small cell lung cancer

KW - Transformation

UR - http://www.scopus.com/inward/record.url?scp=84887020905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887020905&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2013.06.003

DO - 10.1016/j.lungcan.2013.06.003

M3 - Article

C2 - 24012411

AN - SCOPUS:84887020905

SN - 0169-5002

VL - 82

SP - 370

EP - 372

JO - Lung Cancer

JF - Lung Cancer

IS - 2

ER -

Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this